Joel Isaacson & Co. LLC Buys 1,058 Shares of Abbott Laboratories $ABT

Joel Isaacson & Co. LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 25.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,150 shares of the healthcare product maker’s stock after buying an additional 1,058 shares during the quarter. Joel Isaacson & Co. LLC’s holdings in Abbott Laboratories were worth $700,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ABT. Hughes Financial Services LLC purchased a new stake in shares of Abbott Laboratories during the first quarter worth about $27,000. Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the first quarter worth about $28,000. Elequin Capital LP purchased a new stake in shares of Abbott Laboratories during the first quarter worth about $30,000. JCIC Asset Management Inc. purchased a new stake in shares of Abbott Laboratories during the first quarter worth about $32,000. Finally, Vision Financial Markets LLC purchased a new stake in shares of Abbott Laboratories during the first quarter worth about $33,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ABT has been the subject of several research analyst reports. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Evercore ISI raised their price objective on shares of Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a report on Tuesday. BTIG Research lowered their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and raised their price objective for the stock from $143.00 to $145.00 in a report on Friday, July 18th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Abbott Laboratories in a report on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $146.24.

Abbott Laboratories Price Performance

ABT stock opened at $133.05 on Wednesday. The firm has a 50 day moving average price of $132.19 and a 200-day moving average price of $131.45. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The firm has a market capitalization of $231.58 billion, a price-to-earnings ratio of 16.67, a PEG ratio of 2.54 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period last year, the business earned $1.14 earnings per share. The business’s revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.